drugset
drugset / Trial / NCT00667654

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

NCT00667654 ↗

Phase 2 Completed 54 enrolled Centrexion Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when delivered as an intra-articular injection in the knee. Secondary objectives will be to explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.

Timeline

Start
2007-08
Primary completion
2008-06
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 100 ug Other
Subject Capsaicin Small molecule 200 ug Other
Subject Capsaicin Small molecule 300 ug Other
Subject Capsaicin Small molecule 425 ug Other
Subject Capsaicin Small molecule 600 ug Other
Subject Capsaicin Small molecule 700 ug Other
Subject Capsaicin Small molecule 800 ug Other
Subject Capsaicin Small molecule 900 ug Other
Subject Capsaicin Small molecule 1000 ug Other

Indications

osteoarthritis, knee